哈尔滨敷尔佳科技股份有限公司 审计报告 德皓审字[2025]00001032 号 北 京 德 皓 国 际 会 计 师 事 务 所 (特殊普通合伙 ) BeijingDehaoInternationalCertifiedPublicAccountants(LimitedLiabilityPartnership) 哈尔滨敷尔佳科技股份有限公司 审计报告及财务报表 （2024 年 1 月 1 日至 2024 年 12 月 31 日止） | | 目录 | 页次 | | --- | --- | --- | | 一、 | 审计报告 | 1-6 | | 二、 | 已审财务报表 | | | | 合并资产负债表 | 1-2 | | | 合并利润表 | 3 | | | 合并现金流量表 | 4 | | | 合并股东权益变动表 | 5-6 | | | 母公司资产负债表 | 7-8 | | | 母公司利润表 | 9 | | | 母公司现金流量表 | 10 | | | 母公司股东权益变动表 | 11-12 | | | 财务报表附注 | 1-67 | 审 计 报 告 德皓审字[2025]00001032号 哈尔滨敷尔佳科技股份有限公司全体 ...

哈尔滨敷尔佳科技股份有限公司 2024 年度独立董事述职报告 本人宋恩喆，作为哈尔滨敷尔佳科技股份有限公司（以下简称"公司"）第 一届董事会独立董事，已于 2024 年 5 月离任。在任职期间本人严格按照《公司 法》《证券法》等法律法规、中国证监会与深圳证券交易所的相关规定，以及《公 司章程》《独立董事工作制度》等法人治理制度的规定，本着客观、公正、独立 的原则，勤勉尽责，积极发挥独立董事作用，维护公司整体利益和全体股东尤其 是中小股东的合法权益。本人现将 2024 年度任职期间履行独立董事职责情况报 告如下： 一、独立董事的基本情况 宋恩喆，男，汉族，1989 年出生，中国国籍，无境外永久居留权，本科学 历，律师，具备深圳证券交易所上市公司独立董事资格。曾任哈尔滨市动力公证 处公证员助理、黑龙江省浙江商会外联部主管、黑龙江省高级人民法院审监庭书 记员、黑龙江达升律师事务所律师；2021 年 4 月至今，任黑龙江孟繁旭律师事 务所律师。2021 年 3 月至 2024 年 5 月，任公司独立董事。 2024 年度任职期间，本人的任职符合法律法规及《上市公司独立董事管理 办法》《深圳证券交易所上市公司自律监管指 ...

哈尔滨敷尔佳科技股份有限公司 2024 年度独立董事述职报告 本人王孝先，作为哈尔滨敷尔佳科技股份有限公司（以下简称"公司"）独 立董事，报告期内严格按照《公司法》《证券法》等法律法规、中国证监会与深 圳证券交易所的相关规定，以及《公司章程》《独立董事工作制度》等法人治理 制度的规定，本着客观、公正、独立的原则，勤勉尽责，积极发挥独立董事作用， 维护公司整体利益和全体股东，尤其是中小股东的合法权益。现将 2024 年度履 行独立董事职责情况报告如下： 一、独立董事的基本情况 王孝先，男，中共党员，汉族，1963 年出生，中国国籍，无境外永久居留 权，硕士学历，注册会计师，高级会计师（审计），具备深圳证券交易所上市公 司独立董事资格。1982 年 10 月至 1991 年 3 月，曾任黑龙江省新建监狱会计； 1991 年 3 月至 1999 年 10 月，曾任黑龙江省科学技术协会审计室主任；1995 年 11 月至 2009 年 10 月，曾任黑龙江龙科会计师事务所有限公司所长；2009 年 11 月至今，出资设立黑龙江亚太会计师事务所有限公司；2021 年 3 月至今，任公 司独立董事。 报告期内，本人的任职 ...

哈尔滨敷尔佳科技股份有限公司 2024 年度独立董事述职报告 本人姚淑英，作为哈尔滨敷尔佳科技股份有限公司（以下简称"公司"）独 立董事，任职期间严格按照《公司法》《证券法》等法律法规、中国证监会与深 圳证券交易所的相关规定，以及《公司章程》《独立董事工作制度》等法人治理 制度的规定，本着客观、公正、独立的原则，勤勉尽责，积极发挥独立董事作用， 维护公司整体利益和全体股东尤其是中小股东的合法权益。本人现将 2024 年度 任职期间履行独立董事职责情况报告如下： 一、独立董事的基本情况 姚淑英，女，汉族，1965 年出生，民革党员，中国国籍，无境外永久居留 权，本科学历，律师，哈尔滨市第十四届、十五届、十六届人大代表。1988 年 7 月至 1992 年 9 月，曾任黑龙江省政法管理干部学院教师；1992 年 9 月至 2001 年 12 月，曾任哈尔滨市妇女联合会权益部科长；2001 年 12 月至今，任黑龙江 天辅律师事务所律师；2012 年 5 月至今，任哈尔滨市人大司法监察委员会专家、 委员；2016 年 9 月至今，任哈尔滨市人民政府行政复议委员会委员；2018 年 9 月至今，任哈尔滨市仲裁委仲裁员 ...

哈尔滨敷尔佳科技股份有限公司 哈尔滨敷尔佳科技股份有限公司董事会 2025 年 4 月 23 日 1 董事会关于独立董事独立性评估的专项意见 根据《上市公司独立董事管理办法》《深圳证券交易所上市公司自律监管指 引第 2 号——创业板上市公司规范运作》等相关文件规定，哈尔滨敷尔佳科技股 份有限公司（以下简称"公司"）董事会，就公司 2024 年度在任独立董事王孝 先、姚淑英的独立性情况进行评估，并出具如下专项意见： 公司董事会根据独立董事王孝先、姚淑英提交的《独立董事关于独立性的自 查报告》及任职情况对其独立性进行评估，认为王孝先、姚淑英均能够胜任独立 董事的职责要求，其未在公司担任除独立董事以外的任何职务，也未在公司主要 股东公司担任任何职务，与公司以及主要股东之间不存在妨碍独立董事进行独立 客观判断的关系，不存在影响独立董事独立性的情况，符合《上市公司独立董事 管理办法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司 规范运作》等相关文件对独立董事独立性的要求。 ...

Financial Performance - The company reported a significant increase in revenue, with a year-on-year growth of 15% in 2024 compared to 2023[18]. - The company's operating revenue for 2024 reached ¥2,016,975,873.58, representing a 4.32% increase compared to ¥1,933,504,352.30 in 2023[23]. - The net profit attributable to shareholders decreased by 11.77% to ¥661,129,436.27 in 2024 from ¥749,343,813.98 in 2023[23]. - The net profit after deducting non-recurring gains and losses fell by 17.00% to ¥603,843,535.48 in 2024 compared to ¥727,562,738.75 in 2023[23]. - The cash flow from operating activities decreased by 26.16% to ¥609,811,011.34 in 2024 from ¥825,875,198.80 in 2023[23]. - The total revenue for 2024 reached ¥2,016,975,873.58, representing a year-on-year increase of 4.32% compared to ¥1,933,504,352.30 in 2023[94]. - The revenue from the daily chemical industry was ¥1,164,229,146.51, accounting for 57.72% of total revenue, with a year-on-year growth of 7.49%[94]. - Online sales contributed ¥1,108,480,558.67, which is 54.96% of total revenue, showing a significant increase of 20.03% from the previous year[94]. - The offline sales decreased by 10.05% to ¥908,472,232.12, which is 45.04% of total revenue[94]. Market Strategy and Expansion - The company is focusing on expanding its market presence through new product launches and technological advancements in the medical device sector[18]. - The company is exploring strategic acquisitions to bolster its product offerings and market share in the cosmetic and medical device industries[18]. - The company is focusing on channel development, optimizing both online and offline sales strategies to drive revenue growth[55]. - The company is actively expanding its product matrix to include both Class II and Class III medical devices, enhancing its market position[69]. - The company plans to focus on green and sustainable product development as a core competitive dimension in response to evolving consumer demands[135]. - The company is expanding its market share in the sodium hyaluronate product segment through new formulations and product types[105]. - The company is expanding its product offerings in the aesthetic medicine market by developing a class III injectable filler product with improved structural stability and degradation resistance[104]. Research and Development - The company is investing in research and development for innovative skincare products aimed at addressing specific skin conditions[18]. - The company has established a new R&D center in Shanghai, enhancing its independent research capabilities and strategic layout[57]. - The company aims to strengthen its R&D capabilities through collaboration with universities and research institutions, focusing on new materials and technologies[57]. - The number of R&D personnel increased to 58 in 2024 from 27 in 2023, representing a growth of 114.81%[107]. - R&D investment amounted to ¥34,822,834.22 in 2024, up from ¥32,838,801.46 in 2023, with the proportion of R&D investment to operating revenue at 1.73%[107]. - The company has established a multi-omics database for medicinal plants, containing over 1,000 plant resources and 5,000-10,000 compound information entries, enhancing its research capabilities[105]. Product Development - The company launched multiple new products, including whitening masks and anti-wrinkle masks, to meet diverse consumer skincare needs[54]. - The company is focusing on the development of Class II and III medical devices, particularly in skin improvement and injection filling categories[57]. - The company is preparing to design and develop a sodium polyglutamate repair patch, which is expected to provide an 8-hour moisturizing effect and accelerate wound healing[104]. - The company has successfully developed a new NMN raw material, which has been registered with the National Cosmetics Raw Material Registration, registration number 20230044[105]. - The company is developing a new series of products based on Centella Asiatica extracts, which are expected to provide strong moisturizing and soothing effects[105]. Corporate Governance - The governance structure includes a clear division of responsibilities among the shareholders' meeting, board of directors, supervisory board, and management, ensuring compliance with relevant laws and regulations[163]. - The board of directors consists of 5 members, including 2 independent directors, meeting legal requirements and ensuring diligent oversight[166]. - The supervisory board has 3 members, including 1 employee representative, fulfilling its duties to protect the rights of shareholders[167]. - The company actively engages with stakeholders to balance interests and fulfill social responsibilities[168]. - The company adheres to the information disclosure obligations as per relevant laws and regulations, ensuring accurate and timely information dissemination to all shareholders[169]. Future Outlook - The company has outlined a future outlook that includes potential risks and growth opportunities in the upcoming fiscal year[6]. - The company has set a performance guidance for 2025, projecting a revenue growth of 10% to 12%[18]. - The company’s future outlook remains positive, with expectations for growth driven by new product launches and market opportunities[183]. - The company plans to continue its market expansion strategy, focusing on enhancing its product offerings and technological advancements[183].

Financial Performance - The company's revenue for Q1 2025 was ¥301,066,807.47, a decrease of 26.39% compared to ¥409,023,327.96 in the same period last year[4] - Net profit attributable to shareholders was ¥91,384,342.59, down 39.77% from ¥151,726,071.70 year-on-year[4] - The total profit for the current period is 121,839,114.94, down 39.5% from 201,855,917.71 in the previous period[22] - The operating profit for the current period is 121,564,366.63, a decline of 39.7% from 201,497,325.69 in the previous period[22] - The net profit for the current period is 91,384,342.59, a decrease of 39.8% compared to 151,726,071.70 in the previous period[22] - Basic and diluted earnings per share for the current period are both 0.23, down from 0.38 in the previous period[22] Cash Flow - The net cash flow from operating activities was -¥66,164,752.80, a decline of 151.78% compared to ¥127,782,897.03 in the previous year[4] - The cash flow from operating activities shows a net outflow of -66,164,752.80, compared to a net inflow of 127,782,897.03 in the previous period[24] - Cash inflow from investment activities is 650,640,918.41, with a net cash flow of 116,472,903.16, contrasting with a net outflow of -43,749,580.19 in the previous period[24] - The cash flow from financing activities resulted in a net outflow of -434,508,092.77, compared to -200,946.18 in the previous period[24] - The company received cash from investment recovery amounting to 610,000,000.00 during the current period[24] - The company reported other cash inflows related to operating activities of 67,801,825.79, an increase from 34,835,161.18 in the previous period[24] Assets and Liabilities - The total assets at the end of the reporting period were ¥5,964,918,300.73, a decrease of 1.97% from ¥6,084,668,329.15 at the end of the previous year[4] - The total liabilities decreased to CNY 211,161,758.25, down 50.0% from CNY 422,296,129.26 in the previous period[20] - The company's cash and cash equivalents at the end of the period were CNY 1,763,687,214.23, down from CNY 1,838,840,251.92 at the beginning of the period[19] - Inventory increased to CNY 188,611,153.63, up 17.6% from CNY 160,291,765.15 in the previous period[19] - The company's retained earnings rose to CNY 2,373,780,428.02, an increase from CNY 2,282,396,085.43 in the previous period[20] Shareholder Information - The total number of common shareholders at the end of the reporting period is 14,211[13] - Zhang Liguan holds 84.41% of shares, totaling 337,720,000 shares[13] - The top 10 shareholders include Harbin Sanlian Pharmaceutical Co., Ltd. with 18,000,000 shares, representing 4.50%[13] - The total number of restricted shares at the beginning of the period was 341,485,000, with 2,900,000 shares released and 1,950,000 shares added, resulting in 340,535,000 restricted shares at the end[16] - The company has a plan for the release of restricted shares, with specific dates for unlocking[15] Research and Development - Research and development expenses increased by 61.60% to ¥9,792,953.74, reflecting the company's commitment to enhancing R&D investment[9] - Research and development expenses rose to CNY 9,792,953.74, an increase of 61.4% compared to CNY 6,060,108.47 in the previous period[21] Government Subsidies - The company received government subsidies amounting to ¥42,866,221.65, contributing to other income growth of 775.51%[9] Other Financial Metrics - The weighted average return on equity decreased to 1.60%, down 1.07% from 2.67% in the previous year[4] - The company reported a net profit of CNY 43,655,154.72 from other income, significantly higher than CNY 4,986,273.07 in the previous period[21] - Total operating costs increased to CNY 237,454,375.39, up 7.4% from CNY 220,697,574.24 in the previous period[21] Share Transactions - The company has not disclosed any related party transactions among the top shareholders[14] - The company has not participated in any share lending or borrowing activities during the reporting period[14] - The company has a total of 947,300 shares held by shareholder Han Jianhua through a margin trading account[14] - The company has a total of 769,200 shares held by shareholder Wang Jianqiang through a margin trading account[14] - The company has a total of 482,000 shares held by shareholder Li Bin through a margin trading account[14]

证券代码：301371 证券简称：敷尔佳 哈尔滨敷尔佳科技股份有限公司 投资者关系活动记录表 编号：2025-003 | | ☑特定对象调研 分析师会议 | | --- | --- | | 投资者关系活 动类别 | □媒体采访 业绩说明会 | | | □新闻发布会 □路演活动 | | | ☑现场参观 | | | □其他 （请文字说明其他活动内容） | | 参与单位名称 及人员姓名 | 西藏博恩资产管理有限公司 刘尹博 | | 时间 | 2025 年 3 月 13 日 16：00-17：00 | | 地点 | 公司一楼花果山会议室 | | 上市公司接待 | 邓百娇女士 董事、董事会秘书、财务负责人 吴 弘先生 证券事务代表 | | 人员姓名 | | | | 齐鑫鑫女士 IR（投资者关系管理） Q1：请介绍一下目前公司的主要产品情况。 | | | A：目前公司主要业务为专业皮肤护理产品的研发、生产 | | | 与销售，专业皮肤护理产品分为医疗器械类产品与功能性护肤 | | | 品（化妆品）两大类，产品剂型以贴类为主，非贴片类产品覆 | | 投资者关系活 | 盖水、乳、精华、次抛、眼膜等。 | | 动主要内容介 ...

暴利行业持续分化洗牌。 作者 | 贝壳XY 编辑 | 小白 正所谓，爱美之心，人皆有之。如今，美容护理已越发融入人们的日常生活中，其市场需求持续扩 大。国家统计局数据显示，我国化妆品类零售总额在过去二十多年里呈现稳步提升，2023年达到4,14 2亿元，较2011年增长接近3倍。 但2024年1-11月的情况却有些不同，化妆品类零售总额罕见出现负增长，同比下滑了1.3%，莫非化妆 品生意不好做了？ （来源：Choice终端，制表：市值风云APP） 这组数据背后，其实意味着两层含义，其一是化妆品需求的小幅减少，其二则是行业内卷越发严重。 消费需求越发向头部品牌集中，质量不佳、规模较小、生产不良的尾部企业正逐渐被淘汰出局，一场 席卷整个行业的大洗牌或许正在进行。 动荡过后，仍能留在牌桌上的企业必定各有各的看家本领，今天我们便从美容护理板块前十大市值公 司来一探究竟。 参考申万行业分类及截至2024年12月31日的市值排名，前十大公司分别为爱美客（300896.SZ）、珀 莱雅（603605.SH）、华熙生物（688363.SH）、稳健医疗（300888.SZ）、锦波生物（832982.BJ）、 贝泰妮（30095 ...